<div id="readability-page-1" class="page"><h3>Meet Samuel – Your Personal Investing Prophet</h3><ul><li>Start a conversation with TipRanks’ trusted, data-backed investment intelligence </li><li> Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds</li></ul>Wuxi Biologics (Cayman) ( (HK:2269) ) just unveiled an update. WuXi Biologics has resolved to activate its shareholder-approved mandate to repurchase shares on the Hong Kong Stock Exchange, authorizing on-market buybacks of up to US$400 million under its existing and future general repurchase mandates. The board believes the current share price undervalues the company’s intrinsic worth and business prospects, and views the program as a signal of confidence in its outlook, while stressing that any buybacks will depend on market conditions and remain entirely at the board’s discretion. The proposed repurchases, capped by both the 10% mandate limit and the US$400 million budget, are intended to enhance shareholder value without breaching listing, takeover, or Cayman corporate regulations. Management’s move underlines an effort to stabilize the stock and potentially improve capital efficiency, though the company cautions investors that there is no assurance on the timing, size, or execution of any actual share repurchases. The most recent analyst rating on (HK:2269) stock is a Buy with a HK$50.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page. More about Wuxi Biologics (Cayman) WuXi Biologics (Cayman) Inc. is a contract research, development and manufacturing organization serving the global biopharmaceutical industry. The group provides end-to-end biologics services, helping drug developers bring therapies from concept to commercial production, with its shares listed on the Hong Kong Stock Exchange. Average Trading Volume: 28,969,485 Technical Sentiment Signal: Sell Current Market Cap: HK$135.5B For an in-depth examination of 2269 stock, go to TipRanks’ Overview page.</div>

WXXWY

02269

520690

513120

520880

159316

WuXi Biologics has announced a US$400 million share buyback plan on the Hong Kong Stock Exchange, citing undervaluation of its shares. The buybacks will depend on market conditions and are intended to enhance shareholder value while adhering to regulatory limits. The company's management emphasizes confidence in its future prospects, although the timing and execution of repurchases remain uncertain. The latest analyst rating for WuXi Biologics is a Buy with a price target of HK$50.00.

Tip Ranks

WuXi Biologics

WUXI BIO

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

WuXi Biologics Launches US$400 Million Share Buyback Plan